Nurix Therapeutics Inc
Research Nurix Therapeutics Inc (NRIX) on Bullrun: market cap USD 2.47B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNRIX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.47B
- Financial periodFY2025
- RevenueUSD 83.98M
- Revenue growth54.0%
- Net income-USD 264.46M
- Free cash flow-USD 263.47M
Valuation Snapshot
latest market cap is USD 2.47B.
About Nurix Therapeutics Inc
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases;
Frequently asked questions
What is Nurix Therapeutics Inc's market cap?
Nurix Therapeutics Inc's market capitalization is USD 2.47B.
What does Nurix Therapeutics Inc do?
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.